Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19

Type Journal Article Author Caleb P. Skipper Author Katelyn A. Pastick Author Nicole W. Engen Author Ananta S. Bangdiwala Author Mahsa Abassi Author Sarah M. Lofgren Author Darlisha A. Williams Author Elizabeth C. Okafor Author Matthew F. Pullen Author Melanie R. Nicol Author Alanna A. Nascene Author Kathy H. Hullsiek Author Matthew P. Cheng Author Darlette Luke Author Sylvain A. Lother Author Lauren J. MacKenzie Author Glen Drobot Author Lauren E. Kelly Author Ilan S. Schwartz Author Ryan Zarychanski Author Emily G. McDonald Author Todd C. Lee Author Radha Rajasingham Author David R. Boulware URL https://www.acpjournals.org/doi/10.7326/M20-4207 Publication Annals of Internal Medicine ISSN 0003-4819 Date 16/07/2020 Extra Publisher: American College of Physicians Journal Abbr Annals of Internal Medicine DOI 10.7326/M20-4207 Library Catalog acpjournals.org (Atypon) Abstract Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19). Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients. Design: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668) Setting: Internet-based trial across the United States and Canada (40 states and 3 provinces). Participants: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset. Intervention: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo.